Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis - Lack of progression to sclerotic lesions in B cell-deficient mice

被引:127
作者
Russell, PS
Chase, CM
Colvin, RB
机构
[1] Massachusetts Gen Hosp, Dept Surg, Transplantat Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA
关键词
D O I
10.1097/00007890-199712150-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The relative roles of humoral and cell-mediated immunity in generating chronic allograft arteriopathy have been considered for several years. We have sought definitive evidence regarding these questions using heart transplants between mouse strains selected to isolate the effects of each form of immune responsiveness. Methods. B10.BR hearts were transplanted to B cell-deficient recipients that are devoid of immunoglobulins (mu MT). Their vessels were compared with those of transplants to fully reactive recipients of the same genetic background (C57BL/6). Additional evidence came from comparisons in other strain combinations. Results. Transplants to B cell-deficient and normal recipients developed cellular coronary endothelialitis, with destruction of the arterial media, accompanied by the adherence of T lymphocytes and macrophages to endothelial surfaces. In B cell-deficient recipients, there was no centripetal migration of smooth muscle, alpha-actin-positive myointimal cells and little deposition of collagen or ground substance, compared with lesions in fully reactive C57BL/6 recipients in which these changes are prominent. In two other donor-recipient combinations in which anti-donor antibodies are generally undetectable (B10.BR-->B10.A and 129-->C57BL/6), intimal fibrosis was uncommon. However, B10.A recipients became capable of producing fibrous lesions in BIO,BR hearts when given anti-donor, class I antibody by passive transfer, as we have observed previously in scid recipients. Conclusions. Taken together, these findings indicate that endothelialitis is antibody-independent, whereas antibodies potentiate and can be sufficient for fully developed, fibrous, chronic allograft vasculopathy. Therapeutic strategies for controlling chronic lesions must consider inhibition of the humoral response.
引用
收藏
页码:1531 / 1536
页数:6
相关论文
共 20 条
[1]   EXPERIMENTAL GRAFT ARTERIOSCLEROSIS .2. IMMUNOCYTOCHEMICAL ANALYSIS OF LESION DEVELOPMENT [J].
ADAMS, DH ;
WYNER, LR ;
KARNOVSKY, MJ .
TRANSPLANTATION, 1993, 56 (04) :794-799
[2]  
Akyurek LM, 1996, TRANSPLANTATION, V62, P1526
[3]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992
[4]   Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection [J].
Chow, LH ;
Huh, S ;
Jiang, J ;
Zhong, R ;
Pickering, JG .
CIRCULATION, 1996, 94 (12) :3079-3082
[5]  
COLSON YL, 1990, J IMMUNOL, V144, P2975
[6]   PRIMARILY VASCULARIZED ALLOGRAFTS OF HEARTS IN MICE - ROLE OF H-2D, H-2K, AND NON-H-2 ANTIGENS IN REJECTION [J].
CORRY, RJ ;
WINN, HJ ;
RUSSELL, PS .
TRANSPLANTATION, 1973, 16 (04) :343-350
[7]  
ENSLEY RD, 1991, TRANSPLANT P, V23, P1130
[8]   Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection [J].
Geraghty, JG ;
Stoltenberg, RL ;
Sollinger, HW ;
Hullett, DA .
TRANSPLANTATION, 1996, 62 (04) :502-509
[9]  
HAMMOND EH, 1991, TRANSPLANT P, V23, P26
[10]  
HAYRY P, 1992, TRANSPLANT P, V24, P2359